Eli Lilly (NYSE: LLY) sells a broad range of pharmaceuticals treating various diseases, but one portfolio in particular has ...

In a report released today, Joon Lee from Truist Financial assigned a Buy rating to Voyager Therapeutics (VYGR – Research Report). The ...

On Tuesday, Viking Therapeutics Inc (VKTX) stock saw a decline, ending the day at $60.6 which represents a decrease of $-2.37 or -3.76% from the prior close of $62.97. The stock opened at $62.46 and ...

So far this year, Eli Lilly (NYSE: LLY) has been on an absolute tear and is swiftly becoming the world's most prolific ...

In recent trading, Viking Therapeutics Inc (VKTX) stock price has shown some volatility, fluctuating -6.04% over the last five trades and 9.66% over the past 30 trades. This represents a notable shift ...

In good news for those averse to injections, GLP-1 agonist medication is a step closer to being offered in oral pill form, ...

A small player like Viking may also win by attracting a partner or even a company that will offer to acquire the biotech.

AstraZeneca and Viking Therapeutics both presented encouraging data on their obesity pills. Meanwhile, here’s how Americans ...

Viking Therapeutics has more than one highly promising clinical-stage candidate. It doesn't face much in the way of financial barriers to implementing its strategy. It's also a very appealing partner ...

With a gain of more than 531% over the last 12 months, shares of Viking Therapeutics (NASDAQ: VKTX) are a hot commodity, to ...

AstraZeneca’s new obesity pill, licensed from China’s Eccogene last year, has shown initial promise in early-stage trials.

While expected and seen as largely incremental, Jefferies analyst Peter Welford in a Tuesday note to investors said the detailed data for three early-stage assets support moving them into Phase IIb ...